My Authors
Read all threads
The API Industry
✍️ The backbone of India pharma industry is the bulk drug industry
✍️ India has highest no. of US FDA approved plants (665) outside of the US
✍️ India has 44% of global abbreviated new drug applications (ANDA)
✍️ India needs to proactively boost the API Industry
✍️ The Indian pharma industry is the world's 3rd largest in terms of vol
✍️ India's API industry is ranked the 3rd largest in the world
✍️ India fulfils 20% of global demand for generic medicines in terms of Vol & supplies over 60% of global demand of various vaccines & ARV drugs
✍️ Indian bulk drug industry has grown at CAGR of 8.6% over 2016-2020. It is further expeacted to grow at similar CAGR during 2020-2024
✍️ The import of APIs has risen at a CAGR of 8.3% from 2012-2019
✍️ Bulk drug import reached a value of INR ~249 billion in 2019

@Harrshit1
✍️ Imports from China have been on a steady rise over the yrs (Frm 62% in FY12 to 68% in FY19)
✍️ India imported 169 Bn worth of APIs from China in FY19
✍️ High import dependancy is largely attributed to lack of cost-effective options in domestic API mfging as compared to imports
Contribution to Economy
✍️ Provides Employment to 2.7 Mn Ppl
✍️ Generates $11Bn trade surplus every yr
✍️ Amongst the top 5 sectors contributing to the reduction of trade deficit
✍️ 2 Bn FDI inflows over the last 3 yrs
✍️ Dominated by MSMEs which are primary employment generators
✍️ The Indian generics industry can benefit substiantially from the patent cliff as patents for branded molecules with cumulative global sales of over $251 billion are expected to expire b/w 2018 & 2024, opening new opportunities for the industry
#Bulkdrug
@unseenvalue
#API
✍️ India is expected to export bulk drugs worth 303 Bn in FY20
✍️ India accounts for 17.5% of the world's population & bears 20% of the global diseases burden
✍️ 1 in every 3 pills consumed in the US is produced by an Indian generics manufacturer

@unseenvalue
#Pharmaceutical
✍️ The bulk drug industry is highly fragmented with around 1500 plants that manufacture APIs.
✍️ In FY18, top 14-16 players (including large formulation companies) comprised just 16-17 percent of total market share.
✍️ Current market is largely dependent on China for many APIs
High Imports
✍️ Low cost Imports have a gradual erosion of india's mfging capacity of many APIs
✍️ Dependancy on imports can be reduced if India is able to manufacture the APIs in a cost efficient manner
✍️ China is a single supplier for many of the critical intermediates & APIs
Challanges face by Indian API Industry
✍️ Limited government support in the past
✍️ Inadequate infrastructure
✍️ Environemental clearnace issues
✍️ Price control regime (NLEM/DPCO/NPPA)
✍️ Price volatility due to high import dependancy
✍️ Increased Scrutiny of quality compliance
India and China
✍️ China enjoys cost advantage of around 20%-30% over India
✍️ Chinese API market has now over 2000 APIs molecules
✍️ China has more than 7000 APIs manufacturers with annual production capacity exceeding 2 Mn tonnes
✍️ Indin has around 1500 APIs mfging plants
✍️ China's dominant position in the mkt is a result of infrastructure investment, large-scale mfging capacities, cost effieciency, technical capabilities and supportive govt policies
✍️ China implemented a greater no of reforms to improve its business climate in FY19 than India
Cost Comparison India v China
✍️ RM costs in China are 25%-30% lower than India
✍️ Power cost in China is 20% cheaper than India
✍️ Logistics costs in China are lesser than India
✍️ Borrowing cost in China is lesser than India

@npal20 @_N_U_P_K_Y @DIALWEALTH_IN
✍️ Manpower cost in India is 1.8 times lower than China
✍️ Capacity Utilization rate in China 30%-40% higher than India
✍️ Set-up & production costs in China are 15%-20% lower than in India
✍️ Cost of Chinese bulk drug is 20%-30% lower than in India
#Pharmaceuticals
#API
#China
Boosting API Industry
✍️ Recently GOI approved Bulk drug park & Production linked Incentive Scheme for promotion of domestic mfging of 53 critical APIs
✍️ Ease of doing business
✍️ Incentives and subsidies
✍️ Infrastructure development
✍️ Innovation and technical capabilities
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with Ketan ACMA🇮🇳

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!